- Market cap
- $719.18M
- 52w range
- $1.70 - $8.33
- Beta
- 1.06
- Sector
- Healthcare
- Data quality
- 75/100
- fair value estimate
- $3.01
- Margin of safety
- -56.0%
- Moat score
- 12/100
- Return on equity
- -61.0%
- Debt / equity
- 0.03
- Analyst target
- $14.83
- Target upside
- +116.9%
- Analysts
- 6
About Shattuck Labs, Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Valuation
Derived from filed metrics · High confidence (75% of the inputs available)
Moat, fair value and rating computed by our valuation engine (ported from the original Python model).